{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:40:33Z","timestamp":1791268833337,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:00:00Z","timestamp":1428278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:00:00Z","timestamp":1428278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). During the clinical development programme, increases in mean serum creatinine (SCr) of approximately 0.07\u00a0mg\/dL and 0.08\u00a0mg\/dL were observed which plateaued early. This study assessed changes in measured glomerular filtration rate (mGFR) with tofacitinib relative to placebo in patients with active RA.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This was a randomised, placebo-controlled, Phase 1 study (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/NCT01484561\">NCT01484561<\/jats:ext-link>). Patients were aged \u226518\u00a0years with active RA. Patients were randomised 2:1 to oral tofacitinib 10\u00a0mg twice daily (BID) in Period 1 then placebo BID in Period 2 (tofacitinib\u2009\u2192\u2009placebo); or oral placebo BID in both Periods (placebo\u2009\u2192\u2009placebo). Change in mGFR was evaluated by iohexol serum clearance at four time points (run-in, pre-dose in Period 1, Period 1 end, and Period 2 end). The primary endpoint was the change in mGFR from baseline to Period 1 end. Secondary endpoints included: change in mGFR at other time points; change in estimated GFR (eGFR; Cockcroft\u2013Gault equation) and SCr; efficacy; and safety.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>148 patients were randomised to tofacitinib\u2009\u2192\u2009placebo (N\u2009=\u200997) or placebo\u2009\u2192\u2009placebo (N\u2009=\u200951). Baseline characteristics were similar between groups. A reduction of 8% (90% confidence interval [CI]: 2%, 14%) from baseline in adjusted geometric mean mGFR was observed during tofacitinib treatment in Period 1 vs placebo. During Period 2, mean mGFR returned towards baseline during placebo treatment, and there was no difference between the two treatment groups at the end of the study \u2013 ratio (tofacitinib\u2009\u2192\u2009placebo\/placebo\u2009\u2192\u2009placebo) of adjusted geometric mean fold change of mGFR was 1.04 (90% CI: 0.97, 1.11). Post-hoc analyses, focussed on mGFR variability in placebo\u2009\u2192\u2009placebo patients, were consistent with this conclusion. At study end, similar results were observed for eGFR and SCr. Clinical efficacy and safety were consistent with prior studies.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Increases in mean SCr and decreases in eGFR in tofacitinib-treated patients with RA may occur in parallel with decreases in mean mGFR; mGFR returned towards baseline after tofacitinib discontinuation, with no significant difference vs placebo, even after post-hoc analyses. Safety monitoring will continue in ongoing and future clinical studies and routine pharmacovigilance.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>Clinicaltrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/NCT01484561\">NCT01484561<\/jats:ext-link>. Registered 30 November 2011.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0612-7","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T17:20:50Z","timestamp":1427995250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Joel M","family":"Kremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus A","family":"Simon-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny L","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Kon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth L","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Raber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,6]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet."},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med."},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med."},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum."},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med."},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med."},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"R158","DOI":"10.1186\/ar4673","volume":"16","author":"J Isaacs","year":"2014","unstructured":"Isaacs J, Zuckerman A, Krishnaswami S, Nduaka C, Lan S, Hutmacher M, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16:R158.","journal-title":"Arthritis Res Ther."},{"key":"612_CR8","unstructured":"European Medicines Agency CfMPfHU. European Public Assessment Report for Xeljanz, International non-proprietary name: tofacitinib. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002542\/WC500154697.pdf."},{"key":"612_CR9","unstructured":"US Food and Drug Administration CfDEaR. Pharmacology review of NDA, Xeljanz (tofacitinib). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000PharmR.pdf."},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/0091270008330982","volume":"49","author":"N Lawendy","year":"2009","unstructured":"Lawendy N, Krishnaswami S, Wang R, Gruben D, Cannon C, Swan S, et al. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol. 2009;49:423\u20139.","journal-title":"J Clin Pharmacol."},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2133\/dmpk.20.379","volume":"20","author":"N Kimura","year":"2005","unstructured":"Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379\u201386.","journal-title":"Drug Metab Pharmacokinet."},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cpdd.120","volume":"3","author":"KJ Klamerus","year":"2014","unstructured":"Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, et al. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2. Clinical Pharm in Drug Dev. 2014;3:499\u2013507.","journal-title":"Clinical Pharm in Drug Dev."},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"c284","DOI":"10.1159\/000127362","volume":"108","author":"K Karstila","year":"2008","unstructured":"Karstila K, Harmoinen AP, Lehtimaki TJ, Korpela MM, Mustonen JT, Saha HH. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance. Nephron Clin Pract. 2008;108:c284\u201390.","journal-title":"Nephron Clin Pract."},{"key":"612_CR14","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","volume":"38","author":"RD Perrone","year":"1992","unstructured":"Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38:1933\u201353.","journal-title":"Clin Chem."},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function\u2013measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473\u201383.","journal-title":"N Engl J Med."},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1681\/ASN.2009020171","volume":"20","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20:2305\u201313.","journal-title":"J Am Soc Nephrol."},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62\u20138.","journal-title":"Ann Rheum Dis."},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"I McInnes","year":"2011","unstructured":"McInnes I, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med."},{"key":"612_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","volume":"21","author":"K Michaud","year":"2007","unstructured":"Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:885\u2013906.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"612_CR20","first-page":"S32","volume":"28","author":"V Strand","year":"2010","unstructured":"Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients\u2019 lives. Clin Exp Rheumatol. 2010;28:S32\u201340.","journal-title":"Clin Exp Rheumatol."},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum."},{"key":"612_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","volume":"6","author":"F Gaspari","year":"1995","unstructured":"Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol. 1995;6:257\u201363.","journal-title":"J Am Soc Nephrol."},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832\u201343.","journal-title":"Clin J Am Soc Nephrol."},{"key":"612_CR24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0022-5347(17)37891-6","volume":"146","author":"SC Brown","year":"1991","unstructured":"Brown SC, O\u2019Reilly PH. Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard. J Urol. 1991;146:675\u20139.","journal-title":"J Urol."},{"key":"612_CR25","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1097\/00003246-200108000-00008","volume":"29","author":"CM Erley","year":"2001","unstructured":"Erley CM, Bader BD, Berger ED, Vochazer A, Jorzik JJ, Dietz K, et al. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Crit Care Med. 2001;29:1544\u201350.","journal-title":"Crit Care Med."},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00004424-198303000-00015","volume":"18","author":"B Olsson","year":"1983","unstructured":"Olsson B, Aulie A, Sveen K, Andrew E. Human pharmacokinetics of iohexol. A new nonionic contrast medium. Invest Radiol. 1983;18:177\u201382.","journal-title":"Invest Radiol"},{"key":"612_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00004872-199917030-00002","volume":"17","author":"KH Rahn","year":"1999","unstructured":"Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. J Hypertens. 1999;17:309\u201317.","journal-title":"J Hypertens."},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2215\/CJN.06040611","volume":"6","author":"CY Hsu","year":"2011","unstructured":"Hsu CY, Bansal N. Measured GFR as \u201cgold standard\u201d\u2013all that glitters is not gold? Clin J Am Soc Nephrol. 2011;6:1813\u20134.","journal-title":"Clin J Am Soc Nephrol."},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","volume":"12","author":"F Vincenti","year":"2012","unstructured":"Vincenti F, Tedesco SH, Busque S, O\u2019Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1\u00a0year. Am J Transplant. 2012;12:2446\u201355.","journal-title":"Am J Transplant."},{"key":"612_CR30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1681\/ASN.V92310","volume":"9","author":"F Gaspari","year":"1998","unstructured":"Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, et al. Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol. 1998;9:310\u20133.","journal-title":"J Am Soc Nephrol."},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u201352.","journal-title":"J Rheumatol."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0612-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0612-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:35:17Z","timestamp":1728923717000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0612-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0612-7","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,6]]},"assertion":[{"value":"20 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"95"}}